Neglected tropical diseases (NTDs) are allocate substantial funds for a joint, not- international agencies such as WHO,
the most common infections of the for-profit research center in India to ministries of health in disease-endemic
world’s poorest people and the leading develop inexpensive ‘‘antipoverty’’ vac- countries, and the communities themselves
causes of chronic disability and poverty in cines against neglected diseases [7,8]. is key to achieve any ambitious strategy.
low- and middle-income countries [1–3]. Additional efforts to combat NTDs are With a global dialogue now underway, this
NTDs (Table 1) especially affect children also being shared among major multina- is an appropriate time to present an eight-
and young women of reproductive age tional pharmaceutical companies (i.e., point manifesto (‘‘a public declaration of
[4], and consequently deprive them of Novartis, GlaxoSmithKline, Pfizer, Sa- motives and intentions by a government or
their health and economic potential [3]. nofi-Aventis, Merck & Co.) and others by a person or group regarded as having
NTDs also impair agricultural productiv- who have also committed resources and some public importance’’ [2,11]) for
ity and are an important reason why the made investments in research and devel- NTDs.
world’s poorest 1.4 billion people who live opment for these conditions. Thus,
below the poverty line cannot escape although at present only about 10% of 1. All NTDs are ‘‘tool ready’’
destitution and despair [3]. Despite the the global funds required for preventive
devastating effect of these diseases on chemotherapy and NTD mass drug ad- Tools refer partly to the drugs used to
health and development, with evidence ministration have been committed, and treat NTDs in low- and middle-income
that their global burden is as great as that although R&D for NTDs has not even countries, particularly when these are used
of any other serious disease [1–3], finan- reached the so-called 10/90 gap [9,10] as agents of control and elimination
cial support for control and elimination (meaning only 10% of available global through mass drug administration [12].
efforts, as well as research and develop- R&D spending is committed for diseases Today, most of the NTDs have tools that
ment (R&D), have been inadequate [2,5]. that disproportionately affect 90% of the could be implemented now, even if for
Indeed, in Millennium Development world living in low-income and middle- some diseases such tools are far from being
Goal 6 (to ‘‘combat HIV/AIDS, malaria income countries), there is cautious opti- perfect or complete (Figure 1). For exam-
and other diseases’’), NTDs were not even mism that such disparities could diminish ple, each year, hundreds of millions of
specifically mentioned but merely consid- in the coming decade. poor people receive donated or low-cost
ered as part of the ‘‘other diseases’’ [6]. With a combination of funds from the generic drugs, which in some epidemio-
However, policy makers are slowly begin- group of eight (G8) nations, emerging logical environments have led to the
ning to appreciate the importance of economies (e.g., Brazil, India), multina- elimination of lymphatic filariasis (LF),
NTDs. tional companies, and private philanthrop- onchocerciasis, and trachoma [13–15], as
The World Health Organization ic sources, together with a community of well as reduction of morbidity for the three
(WHO) has a new Department of Ne- scientists, physicians, and other healthcare major soil-transmitted helminth infections
glected Tropical Diseases, and WHO- workers, global public health experts and (i.e., ascariasis, trichuriasis, and hookworm
TDR (Special Programme for Research policy makers committed to NTDs have infection), and for schistosomiasis (Table 2)
and Training in Tropical Diseases) has a begun to deliberate about how future [1–3,12]. At present, populations at risk
new 10-year strategic plan with support resources and investments should be best for LF and onchocerciasis are receiving
from UN agencies, member states, and allocated, particularly in terms of an the highest global drug coverage (.40%),
private philanthropies. At the same time, appropriate balance between implementa- whereas less than 10% of school-aged
funding for integrated NTD preventive tion and R&D. The leadership of key children at risk for soil-transmitted hel-
chemotherapy control from the govern-
ments of the US and UK has increased Citation: Hotez PJ, Pecoul B (2010) ‘‘Manifesto’’ for Advancing the Control and Elimination of Neglected
dramatically and is approaching US$100 Tropical Diseases. PLoS Negl Trop Dis 4(5): e718. doi:10.1371/journal.pntd.0000718
million annually, while support remains Published May 25, 2010
strong for product development partner-
Copyright: ß 2010 Hotez, Pecoul. This is an open-access article distributed under the terms of the Creative
ships from the Bill & Melinda Gates Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
Foundation, Médecins Sans Frontières provided the original author and source are credited.
(MSF), and a few European governments. Funding: The authors received no specific funding for this study.
Recently, the new Director of the US Competing Interests: Peter J. Hotez is an inventor on international patents for hookworm and
National Institutes of Health, Francis schistosomiasis vaccines.
Collins, has targeted NTDs as a research Author Information: PJH is Editor-in-Chief of PLoS Neglected Tropical Diseases. He is Distinguished Research
priority, and the UK charity Wellcome Professor at George Washington University and President of the Sabin Vaccine Institute. BP is Executive Director
Trust has agreed with the multinational of DNDi.
pharmaceutical company Merck & Co. to * E-mail: mtmpjh@gwumc.edu (PJH); Bpecoul@dndi.org (BP)
many of these diseases the tools and One of the compounds is fexinidazole However, because of the lack of clearly
implementation strategies available are [36], which has been now been taken all defined efficacy endpoints and no pre-
suboptimal, incomplete, or inadequate to the way from discovery and into clinical dictive animal model, drug development
sustain elimination efforts. Consequently, development. However, because of the for Chagas disease is a very challenging
substantial investments in R&D are ur- high attrition rate in drug development, task.
gently needed to develop new-generation continued efforts in building the HAT For visceral leishmaniasis, the existing
control tools and strategies for their drug pipeline need to be maintained until tools still largely depend on antimonials,
improved use and implementation. new oral drugs are available. which have not yet been optimized to
The currently available drugs for HAT Similarly for Chagas disease, the two reduce toxicity and prevent emerging drug
are highly toxic or need long treatment existing drugs, benznidazole and nifurti- resistance [28,29],. Furthermore, only
regimens and careful patient monitoring, mox, have several limitations in terms of three new effective treatments have been
which are often difficult in resource-poor safety, questionable efficacy in the pre- licensed over the past decade, and even
settings or fragile health systems located in vention of long-term complications asso- these remain largely inaccessible to most
conflict or post-conflict endemic areas ciated with cardiomyopathy and mega- control programs of leishmaniasis in
[22,23,33]. NECT is an efficacious and colon/megaesophagus, and difficult resource-poor settings (Table 2) [39].
easier to administer alternative compared delivery in fragile healthcare systems in Although several combination treatments
to arsenicals or eflornithine alone [23], but the poorest regions of Latin America are under development to prevent the
it is only a temporary suboptimal solution [37,38]. In addition, most patients iden- emergence of drug resistance and to
and better tools are still needed to achieve tified through systematic surveillance are reduce treatment duration, these are not
HAT elimination. The completed genome children, and pediatric formulations do going to be enough for disease elimination.
for African trypanosomes and other ki- not exist, although a nascent program to Therefore, the NTD manifesto mandates
netoplastids offers great potential for the develop a pediatric formulation of benz- urgent action to provide adequate support
development of new drugs [34]. However, nidazole is underway. Based on genomics for the development of such anti-kineto-
there is still a big gap between genomics and proteomics analyses, some new and plastid drugs. Vaccines for all three
data and target identification and valida- promising approaches exist for the devel- kinetoplastid infections are also in early-
tion, and subsequent compound screening. opment of drugs for Chagas disease, stage development, and a recombinant
Several years will be needed to develop including new agents that target ergos- leishmaniasis vaccine is in clinical testing
screening hits that become drug candi- terol and trypanothione biosynthesis, [7,8,40,41]. Similarly, vaccines for other
dates through the lead optimization pro- farnesyl-pyrophosphate synthase, purine nonhelminthic NTDs such as amebiasis
cess. To respond to the urgent needs of salvage pathways, and a unique cysteine and the neglected mycobacterial infections
new, better, and inexpensive treatments protease known as cruzipain [37,38]. As Buruli ulcer and leprosy are in early
for HAT, several product development with HAT, a systematic search for drug development [7,8,42–44], and at least
partnerships and WHO-TDR have initi- candidates from the pipelines of pharma- two live attenuated tetravalent vaccine
ated a systematic search for drug targets ceutical companies has been conducted candidates for dengue fever are in phase
and drugs candidates from existing com- and several antifungal azoles have been 2 clinical trials, with numerous other
pounds made by various pharmaceutical identified as possible clinical candidates vaccine candidates also under develop-
organizations and research institutes [35]. for the treatment of Chagas disease. ment [7,8,45,46].
Chagas disease N Interruption of N Control of non-domicile vectors; s N Strategies for control of N Pediatric benznidazole could be
transmission through vector N Sustained vector control non-domicile vectors available soon
control and improved blood N Millions infected at risk of disease N Better drugs and diagnostics N New compounds in
transfusion development
Dengue N Active surveillance and N Poor mosquito control N Better methods for N Vaccines in development
case management N Increase in man-made risk factors mosquito control
N Selective vector control N Case management in epidemics N Better tools: vaccines,
drugs, case management
Human African N Active surveillance, case N Poor surveillance N Better tools: drugs and N Development of simplified
trypanosomiasis finding and treatment N Poor diagnostics diagnostics HAT treatment: NECT
(HAT) N Selective vector control N Toxic drugs N Fexinidazole in
development stage
Leishmaniasis N Case finding and N Long, difficult, expensive treatment N Better tools: drugs and N Paromomycin, miltefosine,
treatment N Practical limitations of diagnostics diagnostics liposomal amphotericin B
N Selective vector/animal N Low priority N Better case-finding and N Combination therapies
reservoir control, elimination (cutaneous leishmaniasis) treatment strategies N Vaccine in development
in the Indian subcontinent N Poor health systems N Anti-leishmania vaccine
Leprosy N Case-finding and N Incomplete multi-drug N Integration of N Elimination achieved
multi-drug treatment treatment coverage leprosy control in many countries
N Integrating/sustaining control N Improved diagnosis of N Re-evaluation of
N Impact on transmission infection elimination targets
not known N Simplified multi-drug
treatment regimen
N Possible BCG vaccination
strategies
Lymphatic N Interruption of N Elimination target by 2020 N Shorten duration of control N Elimination of transmission
filariasis transmission through N Limited effect of current drugs measures in several countries
periodic mass treatment N Co-endemicity N Drugs that kill/sterilize adult N Ivermectin donation (Merck)
N Disability alleviation (loa loa, onchocerciasis) worms (macrofilaricide) and albendazole (GSK)
by local hygiene N New detection methods N Some antibiotics (tetracycline,
rifampicin) found effective
Onchocerciasis N Periodic mass treatment N Need to sustain high coverage N Drugs that kill/sterilize N Ivermectin donation (Merck)
to eliminate the disease as N Eradication not possible with adult worms (macrofilaricide) N Some antibiotics (tetracycline,
a public health problem current tools N Shorten duration of control rifampicin) found effective
N Limited effect of current drug measures N Moxidectin in
N Over-reliance on one single drug N New detection methods development stage
N Co-endemicity (loa loa) N Resistance markers N Control in ten west
African countries
N No new cases of blindness due
to onchocerciasis in the Americas
in the past decade
Soil-transmitted N Morbidity control N WHO target to treat .75% N Operational research to N New antihelminthic drugs
Helminth Infections through periodic mass school-age children at risk integrate with other NTD N Human hookworm vaccine
treatment N Inclusion of pre-school control efforts and to in development
children (,5 y) improve coverage
N Low cure rates with single dose N Better drugs or
N Over-reliance on one single drug combination of drugs
N Better control measures
N Resistance markers
N Antihelminthic vaccines to
prevent re-infection and
forestall drug resistance
Schistosomiasis N Morbidity control through N WHO target to treat .75% N Operational research to N Antimalarial drugs found
periodic treatment in high-risk school-age children at risk integrate with other NTD control effective
populations N Limited availability of praziquantel efforts and to improve coverage N New drug candidates
N Over-reliance on one single drug N Better drugs or combinations N Decreased prevalence in some
N Resistance markers countries
N Antihelminthic vaccines to N Partial donation of
prevent re-infection and praziquantel (Merck KGaA)
forestall drug resistance N At least two vaccines in
development
Trachoma N SAFE (surgery, antibiotics, N Global elimination of trachoma N Operational research to N Elimination in selected
face washing, environmental by the year 2020 integrate with other NTD control countries
control) strategy N Over-reliance on one single drug efforts and to improve coverage
doi:10.1371/journal.pntd.0000718.t002
References
1. Hotez PJ, Molyneux DH, Fenwick A, 5. Moran M, Guzman J, Henderson K, Ropars A-L, 10. TDR/Gen/96.1. Geneva: World Health
Kumaresan J, Ehrlich Sachs S, et al. (2007) McDonald A, et al. (2009) G-Finder: Neglected Organization.
Control of neglected tropical diseases. Disease Research & Development: New Times, 10. Chirac P, Torreele E (2006) Global framework on
N Engl J Med 357: 1018–1027. New Trends; Health Policy Division, The George essential health R&D. Lancet 367: 1560–1561.
2. Hotez PJ (2008) Forgotten People, Forgotten Institute for International Health. 101 p. 11. Webster’s New World College Dictionary Fourth
Diseases: the Neglected Tropical Diseases and 6. United Nations (2009) The Millennium Develop- Edition 2000.
their Impact on Global Health and Development. ment Goals Report. Available. http://www.un.org/ 12. Hotez PJ (2009) Mass drug administration and
ASM Press 218. millenniumgoals/pdf/MDG_Report_2009_ENG. integrated control for the world’s high-prevalence
3. Hotez PJ, Fenwick A, Savioli L, Molyneux DH pdf. Accessed 27 Apr 2010. neglected tropical diseases. Clin Pharmacol
(2009) Rescuing the bottom billion through control of 7. Hotez PJ, Ferris MT (2006) The antipoverty Therap 85: 659–664.
neglected tropical diseases. Lancet 373: 1570–1575. vaccines. Vaccine 24: 5787–5799. 13. [No authors listed] (2008) Global programme to
4. Hotez PJ (2009) Empowering women and im- 8. Hotez PJ, Brown AS (2009) Neglected tropical eliminate lymphatic filariasis. Wkly Epidemiol
proving female reproductive health through disease vaccines. Biologicals 37: 160–164. Rec 83: 333–341.
control of neglected tropical diseases. PLoS Negl 9. Ad Hoc Committee on Health Research Relating 14. Diawara L, Traoré MO, Badji A, Bissan Y,
Trop Dis 3: e559. doi:10.1371/journal.pntd. to Future Intervention Options (1996) Investing Doumbia K, et al. (2009) Feasibility of onchocer-
0000559. in health research and development. Document ciasis elimination with ivermectin treatment in